Your session is about to expire
← Back to Search
TEV-48574 for Inflammatory Bowel Disease
Study Summary
This trial will evaluate the efficacy, safety, and tolerability of a new drug for treating adults with IBD over a period of 26 weeks and 30 months.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I expect to need major surgery during the study.I left the TV48574-IMM-20036 study early for personal reasons or due to the treatment.I showed improvement or remission at week 14 of my previous study.
- Group 1: TEV-48574 Dose Regimen A for Ulcerative Colitis (UC)
- Group 2: TEV-48574 Dose Regimen A for Crohn's Disease (CD)
- Group 3: TEV-48574 Dose Regimen B for Ulcerative Colitis (UC)
- Group 4: TEV-48574 Dose Regimen B for Crohn's Disease (CD)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are individuals aged thirty and over eligible to join this trial?
"Conforming to the eligibility criteria for this trial, the youngest permitted participant is 18 years old and the oldest accepted patient is 75."
Has the FDA cleared TEV-48574 Dose Regimen A for Crohn's Disease (CD) treatments?
"Considering the evidence gathered in Phase 2 trials, TEV-48574 Dose Regimen A for Crohn's disease (CD) received a safety score of two. This signifies that there are some data points indicating its security but insufficient proof to suggest efficacy."
Are there any vacancies for test subjects in this trial?
"Affirmative. Clinicaltrials.gov holds evidence that this medical experiment is still enrolling participants, with the first post dating back to November 1st 2023 and the last edit made on February 2nd2023. This clinical trial aims to recruit 128 individuals from one single location."
How many people have enrolled in this investigation thus far?
"Affirmative. The information posted on clinicaltrials.gov affirms that this medical trial is presently recruiting individuals for participation. It was initially listed on the 11th of January 2021 and most recently amended on the 2nd of February 2021. This study seeks to enrol 128 patients from a single site."
Is there a way to join this clinical trial?
"This trial seeks 128 individuals diagnosed with ulcerative colitis, aged between 18 and 75. The specific requirements for enrolment include demonstrating clinical response or remission during the 14-week TV48574-IMM-20036 DRF study as well a negative β-human chorionic gonadotropin test result for women of childbearing potential, who must also practice effective contraception methods. Moreover, male participants in such partnerships are expected to use condoms post initial IMP administration until completion of the research project. More details can be acquired by contacting the lead investigator directly."
Share this study with friends
Copy Link
Messenger